|Staff Category:||Postdoctoral Fellow|
|Contract Duration:||2 years (with possible extension for 1 year)|
|Closing Date:||8 September 2019|
The research group of Lars Steinmetz seeks for a highly motivated postdoctoral fellow to lead the experimental work on an intersectoral functional genomics project with the aim to dissect the genetic basis of immune diseases. This project will be funded by the Open Targets initiative, a public-private collaboration between academic labs and industrial partners.
Our project aims to develop a deep understanding of immune disease etiology by applying state-of-the-art single-cell transcriptomics and CRISPR/Cas9 technologies to disease-relevant primary cell culture model systems. You will lead study design and perform experiments, including large-scale functional genomics screens and single-cell transcriptomics in human T-cells and other cells of the immune system. The project will be strongly supported by a dedicated computational scientist, along with our industry partners at GSK/Cellzome.
Candidates should have a Ph.D. in a relevant field with strong expertise in molecular biology, next generation sequencing technologies, and CRISPR/Cas9. We especially ask for applications from candidates with a background in immunology, with experience in enriching, culturing, and manipulating immune cells. The appointed candidate should be capable of building and maintaining strong professional relationships with our collaborators in academia and industry, while being well-positioned to lead the project at all stages. (S)he will be highly motivated, creative, and well organized. Excellent communication skills in oral and written English are highly essential.
Why join us
The proposed project will provide the successful applicant with a unique possibility to work at the intersection of academic and industrial research, acquiring deep experience in cutting-edge technologies and a highly relevant research area, and to build a strong network with our industry collaborators.
What else you need to know
EMBL, Europe’s flagship laboratory for the life sciences, is an intergovernmental research institute with more than 80 independent research groups across six sites in Europe. The Steinmetz Lab works across two sites at EMBL Heidelberg and Stanford University and is one of the world’s leading labs in technology development for functional genomics, by combining experimental work and bioinformatics. Open Targets (www.opentargets.org) is a pioneering partnership between EMBL-EBI, GSK, the Wellcome Sanger Institute, Celgene, Sanofi, and Takeda, bringing together expertise of six complementary institutions. OpenTargets provides an R&D framework to improve the success rate for discovering new medicines, by generating evidence on the biological validity of therapeutic targets using genome-scale experiments and analysis.